RxDoctor Payments Data

Kimberly Abbott

Family · Prairieville, LANPI 1740203041

Payments from drug & device makers

$2,457in general payments, 2019–2025

Across 158 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$678
  • Amarin Pharma, Inc.$222
  • Takeda Pharmaceuticals U.S.A., Inc.$171
  • Bayer$169
  • Genentech USA, Inc.$134
  • Pfizer$127
  • plus $956 from 23 others

What the payments were for

  • Food & beverage$2,457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,457 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$18,052
Medicare patients
58
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$55,350
JardianceEmpagliflozin18$31,845
MyrbetriqMirabegron13$8,399
Albuterol Sulfate HfaAlbuterol Sulfate43$1,330
Atorvastatin Calcium136$1,291
Buspirone Hcl92$1,147
Ibandronate Sodium20$1,061
Levothyroxine Sodium128$845
Escitalopram Oxalate52$832
Azelastine Hcl18$825
Sertraline Hcl70$799
Metoprolol Succinate44$752
Rosuvastatin Calcium59$716
Pravastatin Sodium53$711
Olmesartan Medoxomil51$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103$55,35051 claims
Boehringer IngelheimJardiance$20$31,84518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Prairieville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →